Bot Image
Bot Image is a medical AI software company that develops ProstatID, an FDA-cleared SaaS platform using proprietary machine learning to detect, diagnose, and screen prostate cancer from biparametric MRI, serving hospitals, imaging centers, urology practices, and patients via platform partners and a direct-to-consumer channel.
- Company typePrivate
- Founded2019
- HeadquartersOmaha, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Bot Image does
Bot Image, Inc. is a medical imaging AI company that develops and commercializes ProstatID, an FDA 510(k)-cleared, CE Mark-certified, and UKCA-certified SaaS medical device for prostate cancer screening, detection, and diagnosis. The software analyzes biparametric MRI (bpMRI) studies—T2-weighted, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) sequences—using a proprietary boosted parallel Random Forest (bpRF) ensemble algorithm trained on more than 1,000 biopsy-confirmed cases with over 6,000 pathology-verified biopsy points. ProstatID automatically detects, segments, and classifies suspicious lesions, appending colorized 2D overlays and 3D lesion visualizations directly to a facility's PACS in under five minutes with no manual workflow steps, and is cleared for use across GE, Siemens, and Philips 1.5T and 3.0T MRI platforms.
Bot Image firmographics
Firmographics- Name
- Bot Image
- Legal name
- Bot Image, Inc.
- Website
- https://botimageai.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bot Image is a medical AI software company that develops ProstatID, an FDA-cleared SaaS platform using proprietary machine learning to detect, diagnose, and screen prostate cancer from biparametric MRI, serving hospitals, imaging centers, urology practices, and patients via platform partners and a direct-to-consumer channel.
- Ownership category
- akta.pro rank
Bot Image industry classification
Industry- Product category
- Medical Imaging AI Software
- NAICS
- Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)
- akta.pro secondary industries
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Medical Imaging AI (HDAAAEAH)
Keywords
Where Bot Image is headquartered
LocationHeadquarters
- HQ city
- Omaha
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Bot Image business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Revenue model
- Per-Click SaaS Pricing: ProstatID is offered as a SaaS medical device AI software on a per-click or per-study basis. Healthcare facilities pay a per-case fee for each prostate MRI processed. The company states per-case cost is more than covered by additional billing associated with use of CAD and/or substitution of ProstatID over MRA or contrast.
- Platform Distribution Revenue Share: Bot Image provides software capacity and expansion through platform distributors (Blackford, TeraRecon, Ferrum) who bear all capacity costs. Bot Image pays a percentage of sales to these distributors for their worldwide sales force support. This model minimizes Bot Image's staffing requirements for customer service.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Per-case SaaS pricing for healthcare facilities |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels6 records
Bot Image product offering
Product offeringCore offering
Bot Image develops and sells ProstatID, an FDA-cleared, cloud-based AI software (SaaS medical device) that analyzes biparametric prostate MRI studies for the screening, detection, and diagnosis of prostate cancer. The software is offered on a per-click/per-study basis to hospitals, imaging centers, and urology practices, integrating with PACS systems via a zero-click workflow. A separate patient-facing service, DeepView Imaging, lets individual patients upload existing prostate MRIs for AI-supported analysis powered by ProstatID.
Product overview
Bot Image offers a focused product portfolio anchored by ProstatID, North America's first FDA-cleared AI software for prostate cancer screening, detection, and diagnosis. ProstatID is a SaaS medical device that integrates with healthcare facility PACS systems to provide AI-powered analysis of prostate MRI studies. The company also offers DeepView Imaging, a separate patient-facing pathway that enables patients with existing MRIs to access ProstatID-powered analysis.
Differentiator
Problem solved
Functional benefit
Products and services
- ProstatID FDA-cleared AI software (SaaS medical device) that analyzes biparametric prostate MRI studies (T2W, DWI, ADC) for the screening, detection, and diagnosis of prostate cancer. It automatically detects, segments, and classifies lesions, returns colorized 2D overlays and 3D visualizations with a Gleason-aligned risk index, and integrates with PACS via a zero-click workflow in under five minutes. Targeted at hospital radiology departments, imaging centers, and urology practices.
- DeepView Imaging A separate, patient-facing service powered by ProstatID that allows patients (or their physicians) with an existing prostate MRI to upload DICOM files and receive an AI-supported analysis report with visual overlays for discussion with their treating radiologist, urologist, or clinician. Results are returned for physician discussion without requiring a referral.
Quantifiable outcome
- 93.6% standalone AUROC sensitivity-specificity vs. 75.9% for best participating radiologist in clinical studies
- +5 more outcomes
Companies that use Bot Image
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles3 records
Bot Image technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature6 records
Bot Image partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and supporting.
- DeepView ImagingcoreDeepView Imaging is a separate patient-facing service powered by ProstatID. Through this partnership, patients can securely upload their prostate MRI and receive an AI-supported analysis report with visual overlays to share with their physician. DeepView Imaging is a service of Precision Prostate Consulting, LLC.
- ConcertAI's TeraReconcoreTeraReon's Eureka Clinical AI platform integrates ProstatID to provide clinicians with state-of-the-art AI and deep learning technology for prostate cancer screening and detection using bpMRI. This partnership enables deployment through TeraReon's established healthcare platform.
- BlackfordcoreBlackford partnered with Bot Image to add ProstatID to their extensive AI portfolio. Blackford's CEO Ben Panter stated: 'Bot Image's commitment to the detection and management of prostate cancer is a great fit with our mission to improve the lives of patients by leveraging AI to drive healthcare efficiencies.' Blackford provides global distribution capacity for ProstatID.
- FerrumsupportingFerrum is listed as a partner in Bot Image's ecosystem, appearing alongside Blackford and TeraRecon in the partnership section of the website.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Bot Image competitors and assessment
Company assessmentDirect peers
- Aidoc: Aidoc is a venture-backed radiology AI vendor offering FDA-cleared algorithms across multiple imaging modalities (CT, MRI, X-ray) sold to hospitals and distributed through the same AI platform partners (Blackford, TeraRecon). Highly comparable in business model (per-study SaaS), GTM (enterprise + channel), and customer base (radiology departments, PACS-integrated workflows).
- Lunit: Lunit is a publicly traded Korean medical imaging AI company with FDA-cleared products in cancer detection (notably Lunit INSIGHT for mammography and chest), distributed via PACS partners globally. Closely comparable as a CAD/CADx AI vendor targeting radiologists with regulatory clearances in the US and EU.
- Qure.ai: Qure.ai develops deep-learning algorithms for medical imaging interpretation (head CT, chest X-ray, musculoskeletal) with multiple FDA clearances and CE marks, sold to hospitals and distributed through AI orchestration platforms including Blackford and TeraRecon. Direct comparable in regulatory strategy, channel GTM, and clinical workflow integration.
- Viz.ai: Viz.ai is a venture-scale radiology AI company focused on time-sensitive disease detection (stroke, PE, aortic disease) with FDA-cleared, PACS-integrated SaaS and a per-study commercial model. Comparable in target buyer (hospital radiology), regulatory pathway (510(k) CADe/CADx), and platform-partner distribution.
- Avenda Health: Avenda Health is an AI-focused prostate cancer company (Unfold AI for focal therapy planning) with FDA clearance and urology-channel sales. Closely comparable in therapeutic focus (prostate cancer), clinical buyer (urologists), and AI-imaging-for-cancer workflow, though it skews to treatment planning rather than MRI screening.
- Paige.AI: Paige is an AI company applying deep learning to cancer imaging (pathology, with adjacent imaging efforts) with FDA-authorized products sold to hospital pathology and oncology departments. Comparable as a regulated, AI-first cancer-imaging SaaS vendor with similar enterprise sales motion and CPT-driven economics.
- DeepHealth (a RadNet company): DeepHealth, the AI subsidiary of RadNet, develops FDA-cleared imaging AI (mammography, prostate, lung) deployed across a large outpatient imaging network and offered to other providers. Comparable as a radiologist-facing AI imaging vendor with FDA clearances, channel partnerships, and per-study pricing.
- Perspectum: Perspectum develops quantitative MRI AI software (notably LiverMultiScan) sold to hospitals and radiology groups with FDA clearance and CE marking. Comparable as a SaaS medical-device AI vendor using multiparametric MRI to deliver decision-support outputs integrated into radiology reporting workflows.
- Quibim: Quibim is a Spanish medical imaging AI company offering radiomics and AI-based image analysis across oncology (prostate, breast, lung) with CE-marked and FDA-cleared products distributed through enterprise channels. Comparable in imaging-AI focus on cancer, regulatory footprint, and partner-channel GTM.
- Zebra Medical Vision (Nanox): Zebra Medical Vision (now part of Nanox) is an imaging-AI vendor with multiple FDA-cleared algorithms sold to hospitals on per-scan SaaS terms. Comparable as a multi-modality radiology AI vendor competing for the same hospital PACS integrations and using a similar pay-per-use commercial model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Bot Image social profiles
Digital presenceBot Image compliance and trust
Trust signalCompliance4 records
Bot Image financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bot Image leadership team
Management profileNumber of profiles
Profiles9 records
Bot Image funding detail
Funding detailFunding overview
Funding rounds8 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bot Image M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bot Image
What does Bot Image do?
Bot Image develops and sells ProstatID, an FDA-cleared, cloud-based AI software (SaaS medical device) that analyzes biparametric prostate MRI studies for the screening, detection, and diagnosis of prostate cancer. The software is offered on a per-click/per-study basis to hospitals, imaging centers, and urology practices, integrating with PACS systems via a zero-click workflow. A separate patient-facing service, DeepView Imaging, lets individual patients upload existing prostate MRIs for AI-supported analysis powered by ProstatID.
Is Bot Image a public or private company?
Bot Image is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Bot Image founded?
Bot Image was founded in 2019. It employs 1 to 10 people.
Where is Bot Image based?
Bot Image is headquartered in Omaha, United States, in the North America region.
How does Bot Image make money?
Two revenue lines are on record. Per-Click SaaS Pricing is the primary driver. The others are platform Distribution Revenue Share.
Who are Bot Image's main competitors?
Direct peers on record are Aidoc, Lunit, Qure.ai, Viz.ai, Avenda Health, Paige.AI, DeepHealth (a RadNet company), Perspectum, Quibim and Zebra Medical Vision (Nanox).
Does Bot Image have an API?
No public API is recorded for Bot Image.
What industry is Bot Image in?
Bot Image's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 513210 and its SIC code is 7372.